A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

BACKGROUND: Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant transformation, perturbations in cell polarity lead to CLDN18.2 epitopes being exposed on the cancer cell surface. The first-in-class monoclonal antibody, zolbetuximab (formerly...

Descripción completa

Detalles Bibliográficos
Autores principales: Türeci, O, Sahin, U, Schulze-Bergkamen, H, Zvirbule, Z, Lordick, F, Koeberle, D, Thuss-Patience, P, Ettrich, T, Arnold, D, Bassermann, F, Al-Batran, S E, Wiechen, K, Dhaene, K, Maurus, D, Gold, M, Huber, C, Krivoshik, A, Arozullah, A, Park, J W, Schuler, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771222/
https://www.ncbi.nlm.nih.gov/pubmed/31240302
http://dx.doi.org/10.1093/annonc/mdz199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771222/
https://www.ncbi.nlm.nih.gov/pubmed/31240302
http://dx.doi.org/10.1093/annonc/mdz199

Ejemplares similares